Transcriptogen's Unattributed Round

Transcriptogen raised a round of funding on April 14, 2016. Investors include Deepbridge Capital.

Transcriptogen discovers novel TF Inhibitors by first producing the pure protein (or proteins) that comprises the transcription factor complex, and then develops a medium to high-throughput assay base…

Articles about Transcriptogen's Unattributed Round: